Ropinirole Hydrochloride ( DrugBank: Ropinirole )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
6パーキンソン病15
309進行性ミオクローヌスてんかん1

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-152870
11/4/201514/04/2015A parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPAA phase III parallel group comparison study of HP-3000 in patients with Parkinson's disease using L-DOPA Parkinson's diseaseIntervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet
Dosage And administration of the control intervention : Oral, once daily
Control intervention name : Ropinirole hydrochloride extended-release tablet placebo
Dosage And administration of the control intervention : Oral, once daily
Hisamitsu Pharmaceutical Co.,Inc.NULL2079BOTHPhase 3NULL
2JPRN-JapicCTI-142748
11/12/201416/12/2014Long-term study of HP-3000 in patients with Parkinson's diseaseA phase III long-term study of HP-3000 in patients with Parkinson's disease Parkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Hisamitsu Pharmaceutical Co.,Inc.NULL2079BOTHPhase 3NULL
3EUCTR2012-000801-64-GB
(EUCTR)
09/02/201326/11/2012A study of the effects of medication on memory in Parkinson's DiseaseA Phase IV Acceptability and Feasibility Trial of the Effects of Medication on Memory in Idiopathic Nondementing Parkinson’s Disease. - Medication and Memory in Parkinson’s Disease (MeMory PaD) Idiopathic Parkinson's Disease
MedDRA version: 17.0;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Mirapexin extended release various strengths
Product Name: Pramipexole dihydrochloride monohydrate extended release
Product Code: N/A
INN or Proposed INN: pramipexole dihydrochloride monohydrate
Other descriptive name: Mirapexin
Trade Name: Requip prolonged release
Product Name: Ropinirole hydrochloride prolonged release
INN or Proposed INN: Ropinirole (as hydrochloride)
Other descriptive name: Requip XL prolonged-release
University Hospital of North StaffordshireKeele UniversityNot RecruitingFemale: yes
Male: yes
55Phase 4United Kingdom
4JPRN-JapicCTI-121880
11/6/2012Phase II clinical study in patients with Parkinson's disease not taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease not taking L-DOPA Parkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Hisamitsu Pharmaceutical Co.,Inc.NULL2079BOTHPhase 2NULL
5JPRN-JapicCTI-121879
07/6/2012Phase II clinical study in patients with Parkinson's disease taking L-DOPAA randomized, double-blind, placebo-controlled, comparative study of HP-3000 in patients with Parkinson's disease taking L-DOPA Parkinson's diseaseIntervention name : HP-3000(ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Control intervention name : HP-3000 placebo
Dosage And administration of the control intervention : Transdermal, once daily
Hisamitsu Pharmaceutical Co.,Inc.NULL2079BOTHPhase 2NULL
6JPRN-JapicCTI-111673
12/10/201125/10/2011Phase II clinical study in patients with Parkinson's disease.Pharmacokinetic study of HP-3000 in patients with Parkinson's disease. Parkinson's diseaseIntervention name : HP-3000 (ropinirole hydrochloride patch)
Dosage And administration of the intervention : Transdermal, once daily
Hisamitsu Pharmaceutical Co., Inc.NULL2079BOTHPhase 2NULL
7NCT00485069
(ClinicalTrials.gov)
June 200711/6/2007REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 StudyPost-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety -Parkinson Disease;Parkinson's DiseaseDrug: ROP;Drug: ROP+L-DopaGlaxoSmithKlineNULLCompleted20 YearsN/AAll123Phase 4Japan
8EUCTR2005-005423-34-HU
(EUCTR)
04/09/200605/07/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. Parkinson's disease
MedDRA version: 8.1;Level: LLT;Classification code 10061536;Term: Parkinson's disease
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
516Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy
9EUCTR2005-005423-34-DE
(EUCTR)
19/06/200602/03/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. Parkinson's diseaseProduct Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
516Hungary;United Kingdom;Czech Republic;Germany;Spain;Italy
10EUCTR2005-005423-34-ES
(EUCTR)
19/05/200629/03/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. Parkinson's diseaseProduct Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
GlaxoSmithKlineNULLNot RecruitingFemale: yes
Male: yes
516Phase 3Hungary;Czech Republic;Spain;Germany;Italy;United Kingdom
11EUCTR2005-005423-34-GB
(EUCTR)
11/05/200617/03/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. Parkinson's diseaseProduct Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
GlaxoSmithKline Research & Development LtdNULLNot Recruiting Female: yes
Male: yes
516 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noHungary;Czech Republic;Spain;Germany;Italy;United Kingdom
12EUCTR2005-005423-34-CZ
(EUCTR)
20/04/200603/03/2006A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa.A Randomised, Double-Blind, Double-Dummy, Parallel Group Comparison of 24 Weeks of Treatment with Ropinirole Immediate Release (IR) Tablets or Ropinirole Prolonged Release / Extended Release (PR/XR) Tablets in Advanced Stage Parkinson’s Disease Subjects who are not Adequately Controlled on L-dopa. Parkinson's diseaseProduct Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole PR/XR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
INN or Proposed INN: Ropinirole
Other descriptive name: Ropinirole hydrochloride
Product Name: Ropinirole IR Tablets
GlaxoSmithKline Research & Development LtdNULLNot RecruitingFemale: yes
Male: yes
516Hungary;United Kingdom;Germany;Czech Republic;Spain;Italy
13NCT00260793
(ClinicalTrials.gov)
November 20051/12/2005Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's DiseaseOpen Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's DiseaseParkinson's DiseaseDrug: Ropinirole HydrochlorideAgarwal, Pinky, M.D.Colorado Neurology;GlaxoSmithKlineRecruiting25 YearsN/ABoth20Phase 3United States
14NCT00674310
(ClinicalTrials.gov)
February 20045/5/2008A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsA Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed ConditionsParkinson's Disease;Restless Leg SyndromeDrug: Ropinirole HydrochlorideRoxane LaboratoriesNULLCompleted18 Years45 YearsAll29N/ANULL
15NCT00673088
(ClinicalTrials.gov)
February 20045/5/2008A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsA Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted ConditionsParkinson's Disease;Restless Leg SyndromeDrug: Ropinirole HydrochlorideRoxane LaboratoriesNULLCompleted18 Years45 YearsAll30N/ANULL

309. 進行性ミオクローヌスてんかん


臨床試験数 : 11 薬物数 : 15 - (DrugBank : 2) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 9
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2007-003210-33-FI
(EUCTR)
03/08/200713/06/2007Effect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg typeEffect of ropinirole hydrochloride in progressive myoclonic epilepsy of Unverricht–Lundborg type Progressive myoclonus epilepsy of the Unverricht–Lundborg disease (ULD) type
MedDRA version: 9.1;Level: PT;Classification code 10054895;Term: Baltic myoclonic epilepsy
Trade Name: Requip
Product Name: Ropinirole hydrochloride
Other descriptive name: ROPINIROLE HYDROCHLORIDE
Department of Neurology, Turku University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
15Finland